Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Urologic oncology

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2007.05.014PMID 18367113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

  2006cited by this paper
• The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.

  2006cited by this paper
• A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.

  2005cited by this paper
• Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study.

  2003cited by this paper
• The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study

  2003cited by this paper
• Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.

  2003cited by this paper
• Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.

  2002cited by this paper
• Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

  2002cited by this paper
• Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.

  2002cited by this paper
• Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.

  2002cited by this paper
• Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy.

  2002cited by this paper
• Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.

  2001cited by this paper
• Symptom Indexes to Assess Outcomes of Treatment for Early Prostate Cancer

  2001cited by this paper
• Fatigue in patients with prostate cancer receiving hormone therapy.

  2000cited by this paper
• A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.

  2000cited by this paper
• Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

  1999cited by this paper
• The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate.

  1999cited by this paper
• Changes in quality of life following treatment for early prostate cancer.

  1999cited by this paper
• Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate.

  1998cited by this paper
• Radioisotopic implantation for carcinoma of the prostate: does it work better than it used to?

  1998cited by this paper
• Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.

  1998cited by this paper
• Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy

  1996cited by this paper
• A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.

  1996cited by this paper
• Depression During Hormonal Treatment Of Prostate Cancer

  1995cited by this paper
• Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia.

  1994cited by this paper
• Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.

  1993cited by this paper
• A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.

  1993cited by this paper
• A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia.

  1993cited by this paper
• Zoladex as Primary Therapy in Advanced Pro static Cancer A French Cooperative Trial

  1988cited by this paper

• Kinetics of prostate volume reduction under hormonal treatment: Timing and impact on external beam radiotherapy - A PRISMA-Compliant systematic review.

  2026cites this paper
• Radiotherapy Plus GnRH Analogue Versus High Dose Bicalutamide: A Case Control Study

  2019cites this paper
• Low dose rate prostate brachytherapy

  2018cites this paper
• Image-guided Prostate Brachytherapy

  2018cites this paper
• Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy.

  2018cites this paper
• Brachytherapy in the Management of Prostate Cancer.

  2017cites this paper
• Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.

  2016cites this paper
• Benefits and Harms of Testosterone Replacement Therapy in Hypogonadal Men: A Systematic Review and Network Meta-analysis

  2016cites this paper
• Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients.

  2014cites this paper
• Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

  2014cites this paper
• Safety of antiandrogen therapy for treating prostate cancer

  2014cites this paper
• Étude randomisée d'un régime de dutasteride et de bicalutamide pour la cytoréduction prostatique avant une curiethérapie par implants permanents d'iode-125

  2011influential citation
• Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists.

  2011cites this paper
• Cancer Management and Research Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Update on the Management of Prostate Cancer with Goserelin Acetate: Patient Perspectives

  year unknowncites this paper